Intersect Ent Inc News Today

The Nasal Polyposis Treatment Market refers to the pharmaceutical and medical devices market dedicated to providing treatment options for nasal polyposis. Nasal polyposis is a chronic inflammatory condition characterized by the development of benign growths (polyps) in the nasal cavity and sinuses. These polyps can...

In value terms by 2023-end and is projected to rise at a CAGR of 6.7% until 2033, according to a recently published report by Future Market Insights. By the end of the said forecast period, a valuation of US$ 8.8 billion is expected for the market. A growing geriatric population suffering from chronic rhinosinusitis...

/PRNewswire/ -- Major players in the surgical navigation systems market are B Braun Melsungen AG, Stryker Corporation, Medtronic plc, Siemens AG, Zimmer Biomet...

The global Absorbable Nasal Implants market size was estimated to be US$ 550 million in 2021 and is expected grow at a CAGR of 7.2% between 2023 to 2032.Nasal airway obstruction can be caused by several things, such as a deviated septum, enlarged turbinates, and weakened upper and/or lower lateral nasal wall cartila...

The FTC and DOJ filed lawsuits to block 16 transactions. Of those transactions, 12 were abandoned and six are in various stages of litigation. European Commission held a public consultation to seek views on the draft revised Merger Implementing Regulation

A novel report on global Nasal Polyps market has been recently published by Reports and Data that offers a comprehensive

Analysts at StockNews.com assumed coverage on shares of Intersect ENT (NASDAQ:XENT – Get Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the medical equipment provider’s stock. Intersect ENT Price Performance XENT stock opened at $28.24 on Wednesday. The firm has a market cap of […]

/PRNewswire/ -- Sinus Dilation Devices Market is projected to grow from USD 2.8 billion in 2022 to USD 3.8 billion by 2027, at a CAGR of 6.6% from 2022 to...

The FTC issued two orders for public comment in June 2022 settling allegations that JAB Consumer Partners’ $1.1 billion acquisition of SAGE Veterinary Partners and $1.65 billion acquisition of the parent of veterinary clinic owner Ethos violated federal antitrust laws.

On June 30, the FTC approved a final order settling charges against Medtronic, Inc. for its acquisition of Intersect ENT, Inc. with the intent to protect